Search results

Skip to results

Type

Type

Status 1 selected

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 15 of 52 results for myeloma

  1. Myeloma: diagnosis and management (NG35)

    This guideline covers the diagnosing and managing of myeloma (including smouldering myeloma and primary plasma cell leukaemia) in people aged 16 and over. It aims to improve care for people with myeloma by promoting the most effective tests and treatments for myeloma and its complications.

    NICE guideline
    Last updated
    25 October 2018
    View recommendations

    Sections for NG35

  2. Bortezomib monotherapy for relapsed multiple myeloma (TA129)

    Evidence-based recommendations on bortezomib monotherapy (Velcade) for treating relapsed multiple myeloma in adults.

    Technology appraisal guidance
    Published
    23 October 2007
    View recommendations

    Sections for TA129

  3. Daratumumab monotherapy for treating relapsed and refractory multiple myeloma (TA783)

    Evidence-based recommendations on daratumumab (Darzalex) for relapsed and refractory multiple myeloma in adults.

    Technology appraisal guidance
    Published
    13 April 2022
    View recommendations

    Sections for TA783

  4. Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma (TA680)

    Evidence-based recommendations on lenalidomide (Revlimid) for maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma in adults.

    Technology appraisal guidance
    Published
    3 March 2021
    View recommendations

    Sections for TA680

  5. Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (TA870)

    Evidence-based recommendations on Ixazomib (Ninlaro) with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma.

    Technology appraisal guidance
    Published
    22 February 2023
    View recommendations

    Sections for TA870

  6. Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (TA897)

    Evidence-based recommendations on daratumumab (Darzalex) with bortezomib and dexamethasone for previously treated multiple myeloma in adults.

    Technology appraisal guidance
    Published
    6 June 2023
    View recommendations

    Sections for TA897

  7. Bortezomib and thalidomide for the first‑line treatment of multiple myeloma (TA228)

    Evidence-based recommendations on bortezomib (Velcade) and thalidomide (Thalidomide Celgene) for treating multiple myeloma in adults.

    Technology appraisal guidance
    Published
    27 July 2011
    View recommendations

    Sections for TA228

  8. Panobinostat for treating multiple myeloma after at least 2 previous treatments (TA380)

    Evidence-based recommendations on panobinostat (Farydak) for treating multiple myeloma after at least 2 previous treatments.

    Technology appraisal guidance
    Published
    27 January 2016
    View recommendations

    Sections for TA380

  9. Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma (TA695)

    Evidence-based recommendations on carfilzomib (Kyprolis) with dexamethasone and lenalidomide (Revlimid) for previously treated multiple myeloma in adults.

    Technology appraisal guidance
    Published
    28 April 2021
    View recommendations

    Sections for TA695

  10. Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib (TA586)

    Evidence-based recommendations on lenalidomide (Revlimid) plus dexamethasone for multiple myeloma after 1 treatment with bortezomib in adults.

    Technology appraisal guidance
    Published
    26 June 2019
    View recommendations

    Sections for TA586

  11. Carfilzomib for previously treated multiple myeloma (TA657)

    Evidence-based recommendations on carfilzomib (Kyprolis) for previously treated multiple myeloma in adults.

    Technology appraisal guidance
    Published
    18 November 2020
    View recommendations

    Sections for TA657

  12. Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies (TA171)

    Evidence-based recommendations on lenalidomide (Revlimid) for treating multiple myeloma in adults who have had at least 2 prior therapies.

    Technology appraisal guidance
    Last updated
    26 June 2019
    View recommendations

    Sections for TA171

  13. Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib (TA427)

    Evidence-based recommendations on pomalidomide (Imnovid) for multiple myeloma previously treated with lenalidomide and bortezomib in adults.

    Technology appraisal guidance
    Published
    11 January 2017
    View recommendations

    Sections for TA427

  14. Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable (TA763)

    Evidence-based recommendations on daratumumab (Darzalex) with bortezomib, thalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is suitable.

    Technology appraisal guidance
    Published
    2 February 2022
    View recommendations

    Sections for TA763

  15. Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation (TA311)

    Evidence-based recommendations on bortezomib (Velcade) for treating multiple myeloma before chemotherapy and stem cell transplant in adults.

    Technology appraisal guidance
    Published
    23 April 2014
    View recommendations

    Sections for TA311